期刊
ANTI-CANCER DRUGS
卷 33, 期 1, 页码 E43-E51出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CAD.0000000000001168
关键词
apalutamide; darolutamide; enzalutamide; nmCRPC; nonmetastatic
This study reviewed the use of several novel AR inhibitors in patients with nmCRPC and evaluated the overall survival, incidence and risk of adverse events, adverse-events-related death, and adverse-events-related treatment discontinuation. The use of new hormonal agents improved overall survival despite the increased risk of adverse events. Therefore, careful consideration of the expected adverse events, patients' comorbidities, and maintenance of quality of life is necessary in the decision-making process.
Several novel androgen receptor (AR)-inhibitors have been introduced for nonmetastatic castration-resistant prostate cancer (nmCRPC) treatment, with the improvement of survival outcomes which need to be balanced against the risk of adverse events. We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating enzalutamide, apalutamide and darolutamide in nmCRPC patients, to assess overall survival (OS), incidence and risk of adverse drug events, adverse-events-related death and adverse-events-related treatment discontinuation. We selected three RCTs (SPARTAN, PROSPER and ARAMIS). New hormonal agents administration resulted in better OS, despite the increased risk of several any grade and grade 3-4 adverse events. In the decision-making process, careful evaluation of expected adverse events, patients' comorbidities and maintenance of quality of life are mandatory.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据